A new non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone, is FDA-approved for kidney and heart protection in patients with type 2 diabetes. In this module, we will be introducing the different MRAs that are commercially available and discussing the evidence to support their use in patients with kidney disease. This will include a focus on criteria for use of finerenone in our patients with type 2 diabetes, and the patient-specific considerations of when to use this medication.
Allissa Long, PharmD, BCACP
Assistant Professor, University of Saint Joseph
Dr. Allissa Long is an Assistant Professor of Pharmacy Practice at the University of Saint Joseph in West Hartford, Connecticut. Dr. Long earned her Doctor of Pharmacy from Western New England University College of Pharmacy and Health Sciences in Springfield, Massachusetts. She completed her PGY1 at UConn John Dempsey Hospital and her PGY2 in ambulatory care/academia at Veterans Health Indiana and Butler University. Her clinical specialties include outpatient primary care disease state management and chronic kidney disease.
Disclosures
The following planners and presenters have disclosed a financial relationship with an ineligible company:
- Allissa Long, PharmD, BCACP
- Wendy St Peter, FCCP, FASN, FNKF - Consultant [GSK]
There are no conflicts of interest or financial relationships with an ineligible company that have been disclosed by the rest of the planners and presenters of this learning activity.
All relevant financial relationships have been mitigated.
